

Sikander Ailawadhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6404356/publications.pdf>

Version: 2024-02-01

200
papers

2,584
citations

236925

25
h-index

254184

43
g-index

204
all docs

204
docs citations

204
times ranked

3726
citing authors

#	ARTICLE	IF	CITATIONS
1	Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 425-433.	0.9	0
2	Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1130-1139.	0.9	4
3	A hybrid method of healthcare delivery research and human-centered design to develop technology-enabled support for caregivers of hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2022, 30, 227-235.	2.2	2
4	Plamotamab (XmAb [®] 13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 738-742.	1.3	2
5	Myelomatous ascites and pleural effusion in relapsed multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05329.	0.5	0
6	Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. <i>Blood Cancer Journal</i> , 2022, 12, 46.	6.2	13
7	Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. <i>Hematological Oncology</i> , 2022, 40, 695-703.	1.7	4
8	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	6
9	Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM. <i>Cancer Research</i> , 2022, 82, CT186-CT186.	0.9	2
10	Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. <i>British Journal of Haematology</i> , 2022, 199, 95-99.	2.5	14
11	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect [®] MM Registry. <i>British Journal of Haematology</i> , 2021, 193, 93-100.	2.5	4
12	Ixazomib and lenalidomide maintenance therapy in multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 851-853.	1.8	2
13	Treatment facility volume and patient outcomes in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	1.3	3
14	Challenges of Cellular Therapy During the COVID-19 Pandemic. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 657-672.	1.6	4
15	Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e449-e455.	0.4	19
16	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 355-360.	0.4	5
17	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	4.1	12
18	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.0	32

#	ARTICLE	IF	CITATIONS
19	Mental Health and Chemical Dependency Services at US Cancer Centers. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 829-838.	4.9	4
20	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	12
21	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematology, the, 2021, 8, e794-e807.	4.6	15
22	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncology Practice, 2021, 17, e1382-e1393.	2.9	5
23	Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Annals of Hematology, 2021, 100, 735-741.	1.8	4
24	Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Network Open, 2021, 4, e2032276.	5.9	22
25	Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers. Cancer, 2021, 127, 1770-1778.	4.1	2
26	ARC-12: Phase 1/1b Study to Evaluate Safety and Tolerability of AB308 + Zimberelimab (AB122) in Advanced Malignancies. Blood, 2021, 138, 1409-1409.	1.4	0
27	A Phase 1 Study of CFT7455, a Novel Degradar of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma. Blood, 2021, 138, 1675-1675.	1.4	8
28	Trends in Utilization of Stored Cryopreserved Autologous Peripheral Hematopoietic Cells (APBHC) Intended for a Second (or beyond) Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM): A Single Center Experience. Blood, 2021, 138, 665-665.	1.4	0
29	CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial. Blood, 2021, 138, 1652-1652.	1.4	3
30	Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers, 2021, 13, 5770.	3.7	11
31	REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study. Blood, 2021, 138, 1967-1967.	1.4	0
32	Ocular Toxicity of Commercially Available Belantamab Mafodotin in Patients with Advanced Multiple Myeloma. Blood, 2021, 138, 2711-2711.	1.4	2
33	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). Blood, 2021, 138, 2285-2285.	1.4	0
34	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. Blood, 2021, 138, 2735-2735.	1.4	2
35	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-na ^{ve}) or after Progression on Sequential I and V (Double-Refractory). Blood, 2021, 138, 1560-1560.	1.4	0
36	Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. Clinical Case Reports (discontinued), 2021, 9, e05181.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 773958.	2.8	2
38	Influence of Sociodemographic Factors on Treatment Decisions in Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e115-e129.	2.6	19
39	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 309-317.	1.3	22
40	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	2.8	14
41	Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 272-276.	0.4	16
42	Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1070-1079.	0.9	1
43	Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. <i>Psychosomatics</i> , 2020, 61, 363-370.	2.5	1
44	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. <i>Cancer</i> , 2020, 126, 4332-4340.	4.1	18
45	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. <i>Blood Advances</i> , 2020, 4, 2143-2157.	5.2	27
46	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	2.9	8
47	Use of KRd-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. <i>Case Reports in Hematology</i> , 2020, 1-6.	0.4	5
48	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	2.2	34
49	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. <i>JCO Oncology Practice</i> , 2020, 16, e341-e349.	2.9	11
50	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 3969-3978.	7.0	13
51	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	5.2	16
52	Cost Analysis of R-CHOP versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. <i>Clinical Hematology International</i> , 2020, 2, 117.	1.7	2
53	Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple Myeloma. <i>Anticancer Research</i> , 2020, 40, 5727-5734.	1.1	3
54	Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 72 Td Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US). <i>Blood</i> , 2020, 136, 47-48.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Racial Disparities and Their Impact on Knowledge, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials Among Cancer Patients. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
56	Efficacy of Daratumumab (Dara)-Based Regimens for the Treatment of Plasma Cell Leukemia (PCL). <i>Blood</i> , 2020, 136, 29-30.	1.4	2
57	Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 347-350.	2.5	4
58	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019, 54, 353-367.	2.4	81
59	Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 619-623.	0.4	10
60	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2019, 9, 75.	6.2	43
61	Survival trends in glioblastoma and association with treating facility volume. <i>Journal of Clinical Neuroscience</i> , 2019, 68, 271-274.	1.5	11
62	Updates in prognostication and treatment of Waldenström's macroglobulinemia. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2019, 12, 179-188.	0.9	8
63	Many Shades of Disparities in Myeloma Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 519-529.	3.8	24
64	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 372-380.	0.4	66
65	Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1882391.	0.3	1
66	Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 3974-3985.	7.0	25
67	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 17.	6.2	35
68	Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Therapeutics</i> , 2019, 41, 477-493.e7.	2.5	10
69	Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. <i>Blood Advances</i> , 2019, 3, 2986-2994.	5.2	70
70	Monoclonal antibody utilization characteristics in patients with multiple myeloma. <i>Anti-Cancer Drugs</i> , 2019, 30, 859-865.	1.4	2
71	Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 9-22.	0.4	21
72	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD138-positive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 29-34.	0.4	53

#	ARTICLE	IF	CITATIONS
73	Predictors of palliative treatment in stage IV colorectal cancer. American Journal of Surgery, 2019, 218, 514-520.	1.8	5
74	Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US). Blood, 2019, 134, 1827-1827.	1.4	1
75	Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.). Blood, 2019, 134, 3164-3164.	1.4	3
76	Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 144-144.	1.4	3
77	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	1.4	0
78	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. Blood, 2019, 134, 5610-5610.	1.4	0
79	Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. Annals of Hematology, 2018, 97, 519-528.	1.8	17
80	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
81	Voxtalib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology, 2018, 5, e170-e180.	4.6	44
82	Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer, 2018, 124, 1710-1721.	4.1	40
83	Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Medicine, 2018, 7, 499-507.	2.8	29
84	The Determinants of Palliative Care Use in Patients With Colorectal Cancer: A National Study. American Journal of Hospice and Palliative Medicine, 2018, 35, 1295-1303.	1.4	29
85	A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. Journal of Gastrointestinal Oncology, 2018, 9, 1063-1073.	1.4	9
86	Commentary: Race and Ethnicity in Biomedical Research –“ Classifications, Challenges, and Future Directions. Ethnicity and Disease, 2018, 28, 561-564.	2.3	19
87	Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 711-712.	0.9	1
88	Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Medicine, 2018, 7, 4932-4942.	2.8	25
89	Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Advances, 2018, 2, 1120-1128.	5.2	18
90	Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist, 2018, 23, 1076-1078.	3.7	37

#	ARTICLE	IF	CITATIONS
91	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. <i>Blood Cancer Journal</i> , 2018, 8, 67.	6.2	66
92	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2018, 183, 196-211.	2.5	16
93	Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 576-589.e1.	0.4	10
94	Palliative Care Use Among Patients With Solid Cancer Tumors. <i>Journal of Palliative Care</i> , 2018, 33, 149-158.	1.0	25
95	Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect® MM Registry. <i>Blood</i> , 2018, 132, 3232-3232.	1.4	2
96	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. <i>Blood</i> , 2018, 132, 3244-3244.	1.4	1
97	Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8037-8037.	1.6	1
98	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	1.4	1
99	Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities. <i>Blood</i> , 2018, 132, 4867-4867.	1.4	0
100	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	1.4	2
101	Decreased Physical Activity in Autologous Stem Cell Recipients Leads to Reduced QOL Scores during Hospitalization. <i>Blood</i> , 2018, 132, 5895-5895.	1.4	1
102	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4869-4869.	1.4	0
103	Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States. <i>Blood</i> , 2018, 132, 4861-4861.	1.4	0
104	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	1.4	1
105	Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo. <i>Blood</i> , 2018, 132, 5558-5558.	1.4	0
106	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138.	1.4	0
107	Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome. <i>Blood</i> , 2018, 132, 1911-1911.	1.4	8
108	Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US). <i>Blood</i> , 2018, 132, 4765-4765.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. <i>Blood</i> , 2018, 132, 4764-4764.	1.4	0
110	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. <i>Blood</i> , 2018, 132, 4852-4852.	1.4	0
111	Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States. <i>Blood</i> , 2018, 132, 4868-4868.	1.4	0
112	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. <i>Blood</i> , 2018, 132, 5873-5873.	1.4	1
113	Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 309-316.	2.3	22
114	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	3.0	115
115	Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 3-12.	2.5	5
116	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	7.1	110
117	Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed and refractory Multiple Myeloma in the United States. <i>Clinical Therapeutics</i> , 2017, 39, 1986-2005.e5.	2.5	39
118	Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. <i>Expert Review of Hematology</i> , 2017, 10, 1107-1119.	2.2	18
119	Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant. <i>Annals of Hematology</i> , 2017, 96, 2125-2126.	1.8	4
120	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	2.5	25
121	Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER Medicare analysis. <i>Cancer Medicine</i> , 2017, 6, 2876-2885.	2.8	63
122	Prevalence of BCL-2/(H) Translocation in Healthy African Americans. <i>Annals of Hematology</i> , 2017, 96, 51-55.	1.8	1
123	Extramedullary Solitary Plasmacytoma: Demonstrating the Role of 18F-FDG PET Imaging. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, XD01-XD03.	0.8	11
124	Cardiac Myeloid Sarcoma: Review of Literature. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2017, 11, XE01-XE04.	0.8	9
125	Secondary Cancers in Hodgkin Lymphoma: A Comprehensive Analysis of Incidence and Trends in Survivors. <i>Blood</i> , 2017, 130, 913-913.	1.4	1
126	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. <i>Blood</i> , 2017, 130, 862-862.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Factors Determining Utilization of Stem Cell Transplant (SCT) for Initial Therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare Disparities. Blood, 2017, 130, 860-860.	1.4	0
128	Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics. Blood, 2017, 130, 864-864.	1.4	4
129	Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C). Case Reports in Genetics, 2016, 2016, 1-4.	0.2	0
130	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood, 2016, 128, 2415-2422.	1.4	51
131	Nuances in the Management of Older People With Multiple Myeloma. Current Hematologic Malignancy Reports, 2016, 11, 241-251.	2.3	11
132	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
133	Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 216-228.	1.7	9
134	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
135	Preclinical models of Waldenström's macroglobulinemia and drug resistance. Best Practice and Research in Clinical Haematology, 2016, 29, 169-178.	1.7	4
136	Impact of access to NCI and NCCN designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer, 2016, 122, 618-625.	4.1	21
137	Persistent Racial/Ethnic Disparities in Outcomes for Multiple Myeloma: A SEER-Database Update. Blood, 2016, 128, 1191-1191.	1.4	2
138	Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials. Blood, 2016, 128, 1192-1192.	1.4	2
139	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2016, 128, 1891-1891.	1.4	9
140	Waldenstrom Macroglobulinemia Cells Modulate Mitochondrial Bioenergetics and Induce a Respiratory Hyper-Drive State upon Acquisition of Ibrutinib-Resistance. Blood, 2016, 128, 2761-2761.	1.4	1
141	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). Blood, 2016, 128, 2968-2968.	1.4	4
142	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	1.4	2
143	Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells. Blood, 2016, 128, 3018-3018.	1.4	5
144	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). Blood, 2016, 128, 3250-3250.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Racial Disparity in Drug Utilization Among Multiple Myeloma Patients: A SEER Medicare Analysis. <i>Blood</i> , 2016, 128, 3542-3542.	1.4	1
146	Trends in Disease Presentation, Management, Cost of Care and Outcomes: A Comprehensive Look at Racial Disparities in Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 3544-3544.	1.4	3
147	Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM). <i>Blood</i> , 2016, 128, 3582-3582.	1.4	1
148	Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis. <i>Blood</i> , 2016, 128, 3612-3612.	1.4	1
149	Genomic Variability in Multiple Myeloma (MM) Patients By Race: An Analysis of the Publically Available MmrF Commpass Study Database. <i>Blood</i> , 2016, 128, 4432-4432.	1.4	2
150	Targeting Bcl-2 Enhances the Anti-Tumor Effects of Lenalidomide and Dexamethasone in in Vitro and In Vivo Models of Multiple Myeloma. <i>Blood</i> , 2016, 128, 4480-4480.	1.4	2
151	Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 4485-4485.	1.4	1
152	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. <i>Blood</i> , 2016, 128, 792-792.	1.4	16
153	Psychiatric Comorbidities Are Associated with Increased Cost of Care and Healthcare Utilization in Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016, 128, 1238-1238.	1.4	0
154	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	1.4	0
155	Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab. <i>Blood</i> , 2016, 128, 5946-5946.	1.4	0
156	Immunophenotyping of Waldenström's Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications. <i>PLoS ONE</i> , 2015, 10, e0122338.	2.5	17
157	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	3.0	106
158	Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. <i>Annals of Hematology</i> , 2015, 94, 1603-1604.	1.8	4
159	Multiple asymptomatic colon plasmacytomas: a diagnostic and therapeutic dilemma. <i>Annals of Hematology</i> , 2015, 94, 1061-1062.	1.8	1
160	Targeted inhibition of the deubiquitinating enzymes, <sc>USP</sc>14 and <sc>UCHL</sc>5, induces proteotoxic stress and apoptosis in <sc>W</sc>aldenström macroglobulinaemia tumour cells. <i>British Journal of Haematology</i> , 2015, 169, 377-390.	2.5	55
161	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 578-585.	0.4	27
162	Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 1557-1557.	1.4	2

#	ARTICLE	IF	CITATIONS
163	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	1.4	8
164	Phase I/II Clinical Trial of Lenalidomide in Combination with AT101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL). <i>Blood</i> , 2015, 126, 5299-5299.	1.4	3
165	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 1839-1839.	1.4	1
166	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015, 126, 703-703.	1.4	4
167	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. <i>Blood</i> , 2015, 126, 3039-3039.	1.4	0
168	Induction of Resistance to Proteasome Inhibition Preferentially Switches Survival Dependence from Bcl-2 to XIAP in Preclinical Models of Waldenstrom Macroglobulinemia: Pre-Clinical Rationale for Early Clinical Sequencing of ABT199. <i>Blood</i> , 2015, 126, 4839-4839.	1.4	0
169	Socio-Demographic Parameters Including Race, As Predictors of Depression in Patients with Hematologic Malignancies. <i>Blood</i> , 2015, 126, 4517-4517.	1.4	0
170	Aurora Kinase Is a Therapeutic Target in Ibrutinib-Resistant Waldenstrom Macroglobulinemia: In-Silico Target Identification and in-Vitro Validation. <i>Blood</i> , 2015, 126, 2754-2754.	1.4	2
171	Deep Sequencing Reveals Lack of a Clonal Relationship Between a Metachronous Classical Hodgkin and Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e87-e93.	0.4	4
172	Outcome Disparities among Ethnic Subgroups of Waldenstrom's Macroglobulinemia: A Population-Based Study. <i>Oncology</i> , 2014, 86, 253-262.	1.9	27
173	The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2014, 124, 1689-1689.	1.4	5
174	Acquired in Vitro Resistance to Ibrutinib Is Associated with Transcriptional Re-Programming and Sustained Survival Signaling in Waldenstrom's Macroglobulinemia and Mantle Cell Lymphoma, Independent of BTK Cys481 Mutation. <i>Blood</i> , 2014, 124, 2250-2250.	1.4	3
175	Therapeutic Sensitivity of CD20- Waldenstrom's Macroglobulinemia Cells Is Determined By Underlying Genomic and Epigenetic Events. <i>Blood</i> , 2014, 124, 3115-3115.	1.4	3
176	Secondary Acute Lymphoblastic Leukemia after Primary Solid Organ Malignancy: A SEER Analysis of Incidence and Outcomes. <i>Blood</i> , 2014, 124, 935-935.	1.4	2
177	Methylation Patterns in Waldenstrom's Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and CebpA Family of Transcription Factors. <i>Blood</i> , 2014, 124, 3551-3551.	1.4	2
178	Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute " Waldenstrom Macroglobulinemia 1. <i>Leukemia and Lymphoma</i> , 2013, 54, 387-396.	1.3	21
179	Ethnic Disparities and Their Association With Outcomes In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2917-2917.	1.4	2
180	Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans. <i>Blood</i> , 2013, 122, 1872-1872.	1.4	0

#	ARTICLE	IF	CITATIONS
181	A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1. Blood, 2013, 122, 3111-3111.	1.4	2
182	Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma. Blood, 2013, 122, 5350-5350.	1.4	0
183	Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1174-1182.	1.3	19
184	Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. British Journal of Haematology, 2012, 158, 91-98.	2.5	97
185	Explaining the Excess Risk of Multiple Myeloma in African-Americans. Blood, 2012, 120, 4002-4002.	1.4	1
186	Phase I Study of Lorvotuzumab Mertansine (LM, IMG901) in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM). Blood, 2012, 120, 728-728.	1.4	23
187	Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma and the Impact On Survival. Blood, 2012, 120, 601-601.	1.4	0
188	Ethnic Disparities in Chronic Lymphocytic Leukemia Survival: A SEER Database Review. Blood, 2012, 120, 757-757.	1.4	4
189	Trends in Incidence and Survival of Multiple Myeloma with Second Primary Malignancy,. Blood, 2011, 118, 3958-3958.	1.4	0
190	Outcome Disparities In Waldenstrom's Macroglobulinemia: A SEER Database Analysis. Blood, 2011, 118, 845-845.	1.4	0
191	Variable Risk of Second Primary Malignancy In Multiple Myeloma Patients of Different Ethnicities. Blood, 2011, 118, 678-678.	1.4	0
192	Phase I Study of Lorvotuzumab Mertansine (IMG901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma - A Preliminary Safety and Efficacy Analysis of the Combination. Blood, 2010, 116, 1934-1934.	1.4	10
193	Disease Knowledge In Chronic Myeloid Leukemia (CML) Patients as a Predictor of Compliance to Treatment.. Blood, 2010, 116, 4481-4481.	1.4	2
194	Outcome Disparities In Multiple Myeloma: A SEER-Based Comparative Analysis of Hispanic Patients. Blood, 2010, 116, 396-396.	1.4	1
195	Combination Therapy with BCNU/Etoposide/Melphalan (BEM) as Conditioning Regimen for Autologous Stem Cell Transplant In Multiple Myeloma.. Blood, 2010, 116, 4587-4587.	1.4	0
196	Imatinib Mesylate Plasma Levels Predict Compliance in Patients with Chronic Myelogenous Leukemia.. Blood, 2009, 114, 4274-4274.	1.4	3
197	High-Dose Cyclophosphamide: An Effective Non-Transplant Salvage Option in Relapsed/Refractory Multiple Myeloma.. Blood, 2009, 114, 4947-4947.	1.4	2
198	Ethnic Disparities in Multiple Myeloma: A Comparative Analysis of Hispanic Patients.. Blood, 2009, 114, 4875-4875.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.. Blood, 2009, 114, 4895-4895.	1.4	0
200	Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.. Blood, 2009, 114, 618-618.	1.4	0